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Scabies, the human skin disease caused
by infestation by the mite Sarcoptes scabiei
var. hominis, causes considerable morbidity
and mortality through direct effects and as
a result of secondary bacterial infection.
Scabies is a truly neglected disease, largely
absent from the global health agenda, and
its huge burden of disease is largely
underappreciated. We contend that coor-
dinated, global efforts to control this
ubiquitous pathogenic mite are both
important and achievable.
Why Is Scabies Important?
Scabies affects people of all countries,
particularly the most vulnerable sectors of
society. Children in developing countries
are most susceptible, with an average
prevalence of 5–10% [1]. The highest
incidence is in tropical climates, with rates
of up to 25% overall and up to 50% in
some communities in the South Pacific
and northern Australia [2,3]. Poverty and
overcrowding are the main risk factors,
and outbreaks in institutions and refugee
camps are common [4]. Scabies causes
intense itch, severely affecting sleep and
quality of life [5]. Crusted scabies, a severe
infestation with thousands of mites, is
associated with extremely high risk
of contagion and causes considerable
morbidity [6].
The complications and secondary ef-
fects of scabies cause a huge public health
burden, yet are generally underappreciat-
ed (Figure 1) [7,8]. Infestation is frequently
complicated by bacterial skin infection,
including impetigo, cellulitis, and abscess
due to Streptococcus pyogenes and Staphylococ-
cus aureus (Figure 2). Such bacterial skin
infections predispose to serious suppura-
tive and nonsuppurative sequelae.
Scabies infestation provides an impor-
tant portal of entry for bacteria, and
complement inhibitors from scabies mites
promote bacterial growth in vitro [9].
Bacterial skin infection predisposes to
sepsis and invasive infections. An estimat-
ed 660,000 incident cases of invasive S.
pyogenes occur globally each year, leading
to more than 160,000 deaths [10], and the
numbers are probably at least as great for
S. aureus.
Skin infection with S. pyogenes can also
lead to the nonsuppurative complications
of acute post-streptococcal glomerulone-
phritis (APSGN) and possibly acute rheu-
matic fever. Skin infection is responsible
for approximately 50% of APSGN in
tropical settings [1], estimated at more
than 470,000 cases per year [10]. Out-
breaks of APSGN coincide with those of
scabies [11], and asymptomatic renal
disease is also common [12]. These insults
to the kidney in childhood contribute to
the development of chronic kidney disease
and subsequent renal failure in adulthood
[13]. Community control of scabies, even
without interventions targeting bacterial
skin infection, has been shown to reduce
rates of both streptococcal skin infection
and haematuria [12]. The relationship
between scabies, streptococcal skin infec-
tion, and acute rheumatic fever requires
further examination, but offers one po-
tential explanation for the high rates of
rheumatic heart disease in countries with
high rates of scabies and impetigo, but
low rates of streptococcal pharyngitis
[14].
Scabies imposes a considerable econom-
ic burden on individuals, families, com-
munities, and health systems. Families in
endemic areas spend a substantial portion
of income on treatments, restricting avail-
able funds for food and essential com-
modities [15,16]. Direct costs relate to
treatments, missed employment, frequent
healthcare consultations, and manage-
ment of hospitalised cases including insti-
tutional outbreaks. Further information is
needed to quantify the indirect costs,
including complications in later life.
Current Strategies to Treat and
Control Scabies
Current management of scabies is
centred on identification and treatment
of cases and household contacts, but there
is a paucity of data to support this as an
effective strategy for reducing scabies
prevalence. Diagnosis can be difficult
and is reliant on clinical identification in
most tropical areas [4]. Topical treat-
ments are effective, but the most effective
of these, permethrin [17], is expensive
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[18] and unavailable in many high-
prevalence
areas. Alternative treatments may be
less effective, poorly tolerated, or have
more substantial adverse effects. Topical
regimens are inconvenient, and low
compliance among household contacts
may reduce the effectiveness of contact
treatment, leading to reinfestation [19].
Steps toward Global Control of
Scabies
We contend that global control of
scabies is achievable, despite a number of
impediments. Initial priorities include: i)
raising awareness of scabies and engaging
financial supporters through advocacy; ii)
enhanced clinical and epidemiologic study
to better understand the burden of disease;
and iii) development and implementation
of effective control strategies. An enhanced
and coordinated research program that
involves active collaboration among a
diverse group of stakeholders is crucial to
underpin all of these areas.
The first challenge is to raise the profile
of this ubiquitous but largely ignored
disease. There are a number of hurdles
to overcome to achieve this goal; two are
mentioned here. First, endemic scabies is
primarily a disease of tropical developing
countries, where resources are scarce and
where there are numerous competing
health priorities, often with apparent
higher direct morbidity and mortality.
Second, the impact is spread across a
broad range of clinical disciplines includ-
ing dermatology, infectious diseases, and
paediatrics, with long-term sequelae
spread between nephrology and cardiolo-
gy.
The World Health Organization
(WHO) recognises the need for specific
programs to target neglected tropical
diseases (NTDs), which affect more than
1 billion people and frequently cluster and
overlap in individuals and regions [20].
The Special Programme for Research and
Training in Tropical Diseases (TDR) has
released a global report for research on
global diseases of poverty, including an
agenda for change [21]. Scabies is not
included in this report. We strongly
contend that scabies be added to the
WHO list of global NTDs [22]. Acknowl-
edgment of scabies as an important
communicable disease of poverty will
promote research interest, engage donors,
and encourage the integrated framework
for NTD control to encompass scabies
control.
It is essential to establish an accurate
estimate of the global burden of scabies,
from individual health (including renal
and cardiac morbidity) to the impact on
the community and region. Interpretation
of the few epidemiological studies pub-
lished to date is confounded by differences
in methodology and the lack of harmo-
nised diagnostic criteria. Priorities include
development of validated, practical crite-
ria for diagnosis [23,24]; the establish-
ment of accurate national and interna-
tional reporting systems; quantification
of the impact on health and econo-
mic activity; and further research
into proposed associations with serious
health conditions such as invasive bacte-
rial infections, APSGN, and rheumatic
fever.
Control strategies will require innova-
tion, leadership, collaboration, and a
considerable increase in available resourc-
es. Successful long-term control must
involve addressing the underlying social
determinants of poverty and overcrowd-
Figure 1. Complications of scabies infestation.
doi:10.1371/journal.pntd.0002167.g001
Figure 2. Hand of an adolescent girl in
Fiji, demonstrating scabies infestation
with typical secondary bacterial infec-
tion.
doi:10.1371/journal.pntd.0002167.g002
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ing, and this should be reflected in policy
and advocacy [21]. There is clear overlap
with other NTDs across a range of
domains, including mapping, surveillance,
and effective systemic treatments, and
therefore the ideal control strategy for
scabies would be integrated within the
global and regional strategy for other
NTDs.
New approaches to control, including
mass drug administration, are cause for
some optimism. Mass administration
studies in Panama and northern Australia
have shown that topical permethrin
substantially reduced scabies and impeti-
go prevalence [25–27]. Mass treatment
with oral ivermectin in the Solomon
Islands reduced scabies prevalence from
25% to 1%, with concomitant reductions
in impetigo and haematuria [12]. Oral
ivermectin is an effective treatment for
scabies, commonly used for crusted sca-
bies and institutional outbreaks. Ivermec-
tin has a long history of use, with more
than 1 billion doses distributed by control
programs for onchocerciasis and filiariasis
[28,29], and the possibility of incorporat-
ing scabies treatment within control
strategies for other NTDs is attractive.
However, important issues regarding
ivermectin must be addressed, including
potential for resistance [30,31], cost-
effectiveness, and use in potentially preg-
nant women and small children. Further,
despite its well-documented efficacy, iver-
mectin is not licensed for, or available for,
treatment of scabies in many countries.
Novel treatments such as other macro-
cylic lactones (e.g., oral moxidectin) and
topical herbal compounds warrant further
investigation [4]. Ensuring a supply of
medications to treat scabies and associat-
ed skin diseases in endemic regions will be
critical.
Research is needed to inform each
aspect of control, including biological
research into transmission and pathogen-
esis, clinical research into diagnosis and
treatment, epidemiologic research into
downstream effects, and public health
research to investigate sustainable and
effective control programs. An audit and
publication of current global research,
both biological and clinical, is important
to promote collaboration and integration
of knowledge from diverse fields. The
recently formed Sarcoptes-World Molecu-
lar Network, consisting of parasitologists
from all continents, aims to be a facilitator
of molecular and genetic research on
Sarcoptes species in humans and animals
[32].
International Alliance for the
Control of Scabies
The International Alliance for the
Control of Scabies (IACS) is a recently
formed group from across the globe to
advance the agenda of scabies control.
The alliance is committed to the control of
human scabies infestation, and to promot-
ing the health and well-being of all those
living in affected communities. Initial
membership includes a diverse range of
professionals including clinicians from
high-prevalence areas, public health phy-
sicians, policy makers, and researchers
studying the biology of the parasite, and
continues to grow with identification and
recruitment of further collaborators.
Our first international meeting was held
in November 2012. Representatives from
five continents exchanged ideas on the
priority areas of advocacy, epidemiology,
control strategies, and biological research,
and have developed working groups and
an action plan to progress these themes.
There are many obstacles on the road
toward control of human scabies, but the
effects on children, families, and commu-
nities worldwide, particularly the under-
appreciated downstream effects, are a
strong impetus for us to embark on the
campaign. The willingness of the global
community to collaborate and work to-
gether toward this goal gives us reason to
be optimistic, and we hope that IACS can
provide a focus for future efforts for this
most neglected of diseases.
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